Annual Accounts Receivable
$426.01 M
-$71.00 M-14.29%
01 December 2023
Summary:
Sinovac Biotech annual accounts receivable is currently $426.01 million, with the most recent change of -$71.00 million (-14.29%) on 01 December 2023. During the last 3 years, it has risen by +$175.38 million (+69.97%). SVA annual accounts receivable is now -53.88% below its all-time high of $923.80 million, reached on 31 December 2021.SVA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$370.17 M
-$55.84 M-13.11%
01 June 2024
Summary:
Sinovac Biotech quarterly accounts receivable is currently $370.17 million, with the most recent change of -$55.84 million (-13.11%) on 01 June 2024. Over the past year, it has dropped by -$55.84 million (-13.11%). SVA quarterly accounts receivable is now -73.43% below its all-time high of $1.39 billion, reached on 30 June 2021.SVA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -13.1% |
| 3 y3 years | +70.0% | -73.4% |
| 5 y5 years | +483.8% | +253.2% |
SVA Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -53.9% | +70.0% | -73.4% | at low |
| 5 y | 5 years | -53.9% | +483.8% | -73.4% | +279.3% |
| alltime | all time | -53.9% | -73.4% | >+9999.0% |
Sinovac Biotech Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $370.17 M(-13.1%) |
| Dec 2023 | $426.01 M(-14.3%) | $426.01 M(+0.2%) |
| June 2023 | - | $425.25 M(-14.4%) |
| Dec 2022 | $497.01 M(-46.2%) | $497.01 M(-48.7%) |
| June 2022 | - | $969.56 M(+5.0%) |
| Dec 2021 | $923.80 M(+268.6%) | $923.80 M(-33.7%) |
| June 2021 | - | $1.39 B(+455.8%) |
| Dec 2020 | $250.63 M(+123.6%) | $250.63 M(+47.5%) |
| Sept 2020 | - | $169.90 M(+60.3%) |
| June 2020 | - | $106.01 M(+8.6%) |
| Mar 2020 | - | $97.59 M(-12.9%) |
| Dec 2019 | $112.10 M(+53.6%) | $112.10 M(+7.0%) |
| Sept 2019 | - | $104.81 M(+8.5%) |
| June 2019 | - | $96.58 M(+21.5%) |
| Mar 2019 | - | $79.50 M(+9.0%) |
| Dec 2018 | $72.97 M(+12.8%) | $72.97 M(-27.3%) |
| June 2018 | - | $100.41 M(+55.3%) |
| Dec 2017 | $64.67 M(+33.5%) | $64.67 M(-20.8%) |
| June 2017 | - | $81.62 M(+68.4%) |
| Dec 2016 | $48.46 M(+26.5%) | $48.46 M(+1.9%) |
| Sept 2016 | - | $47.54 M(+60.5%) |
| June 2016 | - | $29.63 M(-26.2%) |
| Mar 2016 | - | $40.13 M(+4.7%) |
| Dec 2015 | $38.32 M(-3.8%) | $38.32 M(-17.2%) |
| Sept 2015 | - | $46.28 M(+4.8%) |
| June 2015 | - | $44.14 M(+4.2%) |
| Mar 2015 | - | $42.36 M(+6.3%) |
| Dec 2014 | $39.85 M(+27.3%) | $39.85 M(-2.4%) |
| Sept 2014 | - | $40.85 M(+17.6%) |
| June 2014 | - | $34.73 M(-4.3%) |
| Mar 2014 | - | $36.28 M(+15.9%) |
| Dec 2013 | $31.31 M | $31.31 M(-18.9%) |
| Sept 2013 | - | $38.60 M(+23.5%) |
| June 2013 | - | $31.25 M(+14.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $27.34 M(+20.6%) |
| Dec 2012 | $22.67 M(+34.5%) | $22.67 M(-10.5%) |
| Sept 2012 | - | $25.32 M(+36.6%) |
| June 2012 | - | $18.53 M(-3.6%) |
| Mar 2012 | - | $19.23 M(+14.1%) |
| Dec 2011 | $16.85 M(-24.7%) | $16.85 M(-23.9%) |
| Sept 2011 | - | $22.13 M(+19.7%) |
| June 2011 | - | $18.48 M(-18.0%) |
| Mar 2011 | - | $22.53 M(+0.7%) |
| Dec 2010 | $22.37 M(-12.4%) | $22.37 M(-31.3%) |
| Sept 2010 | - | $32.58 M(+24.3%) |
| June 2010 | - | $26.21 M(+15.4%) |
| Mar 2010 | - | $22.71 M(-11.1%) |
| Dec 2009 | $25.54 M(+31.1%) | $25.54 M(-30.8%) |
| Sept 2009 | - | $36.92 M(+16.3%) |
| June 2009 | - | $31.74 M(+50.4%) |
| Mar 2009 | - | $21.11 M(+8.3%) |
| Dec 2008 | $19.49 M(+14.9%) | $19.49 M(-21.9%) |
| Sept 2008 | - | $24.96 M(-16.6%) |
| June 2008 | - | $29.93 M(+40.6%) |
| Mar 2008 | - | $21.29 M(+25.5%) |
| Dec 2007 | $16.97 M(+74.6%) | $16.97 M(-13.7%) |
| Sept 2007 | - | $19.66 M(+31.1%) |
| June 2007 | - | $15.00 M(+54.3%) |
| Dec 2006 | $9.72 M(+78.2%) | $9.72 M(+50.8%) |
| June 2006 | - | $6.45 M(+18.2%) |
| Dec 2005 | $5.45 M(+62.7%) | $5.45 M(+40.9%) |
| June 2005 | - | $3.87 M(+15.4%) |
| Dec 2004 | $3.35 M(+129.6%) | $3.35 M(+39.6%) |
| Sept 2004 | - | $2.40 M(+2.0%) |
| June 2004 | - | $2.36 M(+61.3%) |
| Dec 2003 | $1.46 M(+9263.5%) | $1.46 M |
| Apr 2002 | $15.60 K(+59.2%) | - |
| Apr 2001 | $9800.00(>+9900.0%) | - |
| Apr 2000 | $0.00 | - |
FAQ
- What is Sinovac Biotech annual accounts receivable?
- What is the all time high annual accounts receivable for Sinovac Biotech?
- What is Sinovac Biotech quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Sinovac Biotech?
- What is Sinovac Biotech quarterly accounts receivable year-on-year change?
What is Sinovac Biotech annual accounts receivable?
The current annual accounts receivable of SVA is $426.01 M
What is the all time high annual accounts receivable for Sinovac Biotech?
Sinovac Biotech all-time high annual accounts receivable is $923.80 M
What is Sinovac Biotech quarterly accounts receivable?
The current quarterly accounts receivable of SVA is $370.17 M
What is the all time high quarterly accounts receivable for Sinovac Biotech?
Sinovac Biotech all-time high quarterly accounts receivable is $1.39 B
What is Sinovac Biotech quarterly accounts receivable year-on-year change?
Over the past year, SVA quarterly accounts receivable has changed by -$55.84 M (-13.11%)